Clinical Trial Update: Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating partially HLA-matched third-party antigen-specific T-cells for preventing or treating CMV, EBV, and adenovirus infections afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenovirus Infection
• Cytomegalovirus Infection
• Epstein-barr Virus Infection

Drugs mentioned

• Partially HLA-matched Third Party Antigen Specific T-cells

Snippet

Sponsor: University of Sydney | Conditions: CMV Infection, EBV | Phase 1 | Status: UNKNOWN